Targeting T regulatory cells: Their role in colorectal carcinoma progression and current clinical trials

被引：8

作者：

Bandaru, Sai Samyuktha ^{[1
]}

Boyilla, Rajendra ^{[2
]}

Merchant, Neha ^{[3
]}

Nagaraju, Ganji Purnachandra ^{[4
]}

El-Rayes, Bassel F. ^{[4
]}

机构：

[1] Baton Rouge Gen Hosp, Baton Rouge, LA 70809 USA

[2] Christus St Frances Cabrini Hosp, Alexandria, LA 71301 USA

[3] Banasthali Univ, Dept Biosci & Biotechnol, Jaipur 304022, Rajasthan, India

[4] Univ Alabama Birmingham, Sch Med, Dept Hematol & Oncol, Birmingham, AL 35201 USA

来源：

PHARMACOLOGICAL RESEARCH | 2022年 / 178卷

关键词：

T regulatory cells; Tumor microenvironment; Tmmune cells; Progression; Colorectal cancer; COLON-CANCER PATIENTS; PD-L1; BLOCKADE; LYMPH-NODES; MOUSE MODEL; COLITIS; CD4(+); INFLAMMATION; METASTASIS; EXPRESSION; PHENOTYPES;

D O I：

10.1016/j.phrs.2022.106197

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Colorectal cancer (CRC) is classified as the third leading cancer globally and one of the major causes of morbidity and mortality around the world. The interaction of the immune system with the cancer cells plays a vital role in CRC progression. Regulatory T cells (Tregs) are a form of T cells, which regulate and suppress unwanted acti-vation of the immune system and play a major role in preventing autoimmune diseases. Tregs exhibit a signif-icant role in immune modulation during CRC progression through accumulation in the tumor microenvironment (TME) and suppression of immunity against tumor specific antigens promoting tumor progression. The role of Tregs in CRC progression and its interaction with other immune cells within CRC TME and current clinical trials were reviewed in this paper.

引用

页数：7

共 86 条

[1]

Adenomatous Polyposis Coli Defines Treg Differentiation and Anti-inflammatory Function through Microtubule-Mediated NFAT Localization [J].